Johnson & Johnson

The global erythropoietin drugs market is projected to grow at a CAGR of 3.8% from 2024 to 2034, reaching $14.3 billion by 2034. Advances in precision medicine, regulatory reforms for biosimilars, and telemedicine integration are driving market growth. Key players include Amgen, Roche, and Johnson & Johnson. Epoetin Alfa and biosimilars lead the market segments.

QuidelOrtho secures FDA clearance for Vitros Syphilis Assay, aiming to address the syphilis epidemic in the U.S. under new CEO Brian Blaser. The company plans to enhance production, invest in new tech, and expand markets, with a focus on adding new tests like syphilis to its portfolio.

The FDA approved Tremfya (guselkumab) for treating adults with moderately to severely active ulcerative colitis. It's the first dual-acting interleukin-23 inhibitor for this condition, administered as a 200 mg IV dose at weeks 0, 4, and 8. The approval is based on the QUASAR study, showing significant clinical and endoscopic remission rates compared to placebo.

Johnson & Johnson seeks EMA approval for nipocalimab to treat generalized myasthenia gravis (gMG) in patients with MG-causing autoantibodies. Based on Phase 3 Vivacity-MG3 trial data, nipocalimab plus standard care significantly eased disease severity. The therapy aims to accelerate degradation of MG-driving antibodies by blocking FcRn activity, similar to Rystiggo and Vyvgart. Nipocalimab also demonstrated sustained disease control over six months.

FDA approves Johnson & Johnson's Tremfya (guselkumab) for moderately to severely active ulcerative colitis, based on QUASAR study results showing significant clinical and endoscopic remission rates.

The Global Precision Medicine Market report covers industrial and commercial aspects, market driving forces, key players' strategies, and regional landscape. It includes detailed vendor profiles, market trends, share analysis, and forecasts from 2024 to 2032.

Brian Meshkin and Plante Huguenin Lebovic Kahn LLP sue the federal government for $700 million, alleging DOJ misconduct destroyed Proove Biosciences, a company crucial in combating the opioid crisis. The lawsuit highlights government misconduct, including misrepresentation of evidence and violation of constitutional rights, leading to the dismissal of Meshkin's case 'in the interests of justice.'

At ESMO's annual meeting, Pfizer's ponsegromab showed promise in treating cancer cachexia, helping patients regain weight and improve symptoms. Johnson & Johnson's TAR-200, a chemotherapy-releasing device, demonstrated efficacy in bladder cancer, with 42% of patients showing no cancer evidence. BioNTech and Instil Bio presented early data on drugs targeting PD1 and VEGF, similar to Summit Therapeutics' successful trial. Long-term studies revealed Keytruda's superior survival rates over Yervoy in melanoma patients. Scorpion Therapeutics' STX-478 showed potential as a PI3Ka inhibitor with manageable side effects.

Johnson & Johnson's Shockwave Medical launches E⁸ peripheral intravascular catheter in the US for treating calcified femoropopliteal and below-the-knee PAD, including complex CLTI. The catheter uses sonic pressure waves to crack calcium in vessel walls, offering an alternative to traditional angioplasty. Shockwave Medical, acquired by J&J in a $13.1bn deal, has quickly gained market share in both peripheral and coronary angioplasty markets.

Pharma companies face challenges entering beauty due to differences in marketing, storytelling, and sensorial focus. The high revenue multiples and exclusivity of pharma drugs make entering beauty less enticing. Johnson & Johnson's sale of Kenvue exemplifies pharma's preference for splitting over merging with beauty. Smaller biotech companies are seen as disruptors in the beauty industry. The convergence of beauty and pharma concepts offers benefits like enhanced product efficacy and credibility but also faces challenges like complex regulatory environments and higher costs. The future may see pharma driving innovation in beauty through novel molecules and sustainable alternatives, potentially leading to a true convergence between the two industries.